These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36121028)

  • 1. Discussion of "A formal causal interpretation of the case-crossover design" by Zach Shahn, Miguel A. Hernan, and James M. Robins.
    Pfeiffer RM; Gail MH
    Biometrics; 2023 Jun; 79(2):1346-1348. PubMed ID: 36121028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discussion on "A formal causal interpretation of the case-crossover design" by Zach Shahn, Miguel A. Hernán, and James M. Robins.
    Lumley T
    Biometrics; 2023 Jun; 79(2):1349-1350. PubMed ID: 36121113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discussion of "A formal causal interpretation of the case-crossover design".
    Andersen PK; Martinussen T
    Biometrics; 2023 Jun; 79(2):1344-1345. PubMed ID: 36052967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discussion of Identification, Estimation and Approximation of Risk under Interventions that Depend on the Natural Value of Treatment Using Observational Data, by Jessica Young, Miguel Hernán, and James Robins.
    van der Laan MJ; Luedtke AR; Díaz I
    J Causal Inference; 2014 Nov; 3(1):21-31. PubMed ID: 26636024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A formal causal interpretation of the case-crossover design.
    Shahn Z; Hernán MA; Robins JM
    Biometrics; 2023 Jun; 79(2):1330-1343. PubMed ID: 36001285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection Bias with Outcome-dependent Sampling.
    Sjölander A
    Epidemiology; 2023 Mar; 34(2):186-191. PubMed ID: 36722800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the total effect of time-varying predictors in prevention research.
    Bray BC; Almirall D; Zimmerman RS; Lynam D; Murphy SA
    Prev Sci; 2006 Mar; 7(1):1-17. PubMed ID: 16489417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rejoinder: A formal causal interpretation of the case-crossover design.
    Shahn Z; Hernán MA; Robins JM
    Biometrics; 2023 Jun; 79(2):1351-1358. PubMed ID: 36184798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limits for the Magnitude of M-bias and Certain Other Types of Structural Selection Bias.
    Flanders WD; Ye D
    Epidemiology; 2019 Jul; 30(4):501-508. PubMed ID: 31033689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence].
    Morche J; Freitag S; Hoffmann F; Rissling O; Langer G; Nußbaumer-Streit B; Toews I; Gartlehner G; Meerpohl JJ
    Z Evid Fortbild Qual Gesundhwes; 2020 Apr; 150-152():124-133. PubMed ID: 31980320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
    Colditz GA
    Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Introduction of a tool to assess Risk of Bias in Non-randomized Studies-of Exposure (2022)].
    Sun YH; Wang XX; Pei MY; Ma XJ; Ying YY; Zhan SY; Li N
    Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Sep; 44(9):1454-1461. PubMed ID: 37743281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.
    Wang Y; Berlin JA; Pinheiro J; Wilcox MA
    Clin Trials; 2015 Jun; 12(3):265-75. PubMed ID: 25733675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inter-rater reliability and concurrent validity of ROBINS-I: protocol for a cross-sectional study.
    Jeyaraman MM; Rabbani R; Al-Yousif N; Robson RC; Copstein L; Xia J; Pollock M; Mansour S; Ansari MT; Tricco AC; Abou-Setta AM
    Syst Rev; 2020 Jan; 9(1):12. PubMed ID: 31931871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tools for Evaluating and Improving Causal Inference: Introducing JAMA Cardiology Readers to the Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) Tool.
    Huffman MD; Thomas LE
    JAMA Cardiol; 2018 Oct; 3(10):907. PubMed ID: 30073323
    [No Abstract]   [Full Text] [Related]  

  • 17. A potential outcomes approach to defining and estimating gestational age-specific exposure effects during pregnancy.
    Schnitzer ME; Guerra SF; Longo C; Blais L; Platt RW
    Stat Methods Med Res; 2022 Feb; 31(2):300-314. PubMed ID: 34986058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous Selection Bias: The Problem of Conditioning on a Collider Variable.
    Elwert F; Winship C
    Annu Rev Sociol; 2014 Jul; 40():31-53. PubMed ID: 30111904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity analysis of causal inference in a clinical trial subject to crossover.
    Xie H; Heitjan DF
    Clin Trials; 2004 Feb; 1(1):21-30. PubMed ID: 16281459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clarifying selection bias in cluster randomized trials.
    Li F; Tian Z; Bobb J; Papadogeorgou G; Li F
    Clin Trials; 2022 Feb; 19(1):33-41. PubMed ID: 34894795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.